EE152 Cost-Effectiveness Modeling of Lurbinectedin As a Second-Line Therapy in Patients with Small Cell Lung Cancer (SCLC)

Saved in:
Bibliographic Details
Published in:Value in health 2023-06, Vol.26 (6), p.S87-S87
Main Authors: Su, W., Rengarajan, B., Profant, D., Mayo, K., Groff, M., Tremblay, G., Ganti, A.K.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2023.03.455